Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Feb 2022
Update on the new EUSOMA quality indicators for breast cancer
Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )
3 Feb 2022
Lung cancer in India
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
3 Feb 2022
The global impact of the FDA's changing approval standards
Dr Bishal Gyawali - Queen's University, Kingston, Canada
The global impact of the FDA's changing approval standards ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
2 Feb 2022
Tumour agnostic treatments in GI cancer
Dr Nicola Normanno and Dr Katja Schmitz
Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )
1 Feb 2022
ecancer-AORTIC special issue on cancer research training in Africa
Dr Solomon Rotimi - Covenant University, Ota, Nigeria
ecancer-AORTIC special issue on cancer research training in Africa ( Dr Solomon Rotimi - Covenant University, Ota, Nigeria )
27 Jan 2022
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs...
Prof Peter Schmid - Queen Mary University of London, London, United Kingdom
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC ( Prof Peter Schmid - Queen Mary University of London, London, United Kingdom )
27 Jan 2022
Durvalumab plus chemotherapy significantly improved OS in advanced biliary...
Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South...
Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )
27 Jan 2022
Early treatment discontinuation and early oxaliplatin discontinuation for stage...
Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France
Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )
27 Jan 2022
HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in...
Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA
HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )
27 Jan 2022
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant...
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2022
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC
Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
20 Jan 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation